Creative Biolabs is a trusted partner offering a wide range of in vitro diagnostic (IVD) antibody development and production services, as well as immunoassay development services. Supported by our advanced platforms and unparalleled experience, we are able to provide both high-efficient services and high-quality products. Particularly, we offer IVD antibody (pair) development services targeting resistin, a potential marker of bladder cancer.
Introduction of Resistin
Resistin is a cysteine-rich protein and contains 108 amino acids with a weight of 12.5 kDa. Resistin mainly has been studied in mice, where there is compelling evidence linking the protein to insulin resistance, obesity, and type 2 diabetes mellitus. The protein sequences of murine and human resistin are only approximately 60% identical. In mice, resistin is mainly secreted by adipocyte, whereas in humans, it is expressed and/or secreted by mononuclear cells, macrophages, and neutrophils. Studies have shown that the secretion of resistin was upregulated during inflammation and elevated serum resistin level might be a marker of disease activity (e.g., sepsis shock, inflammatory bowel disease).
Fig.1 Resistin as a potential regulator of inflammation. (Filková, 2009)
Resistin Marker of Bladder Cancer
Bladder cancer is one of the most commonly diagnosed malignancies in men and the second biggest cause of cancer-related death worldwide. Recent clinical studies suggest that obesity may promote prostate cancer cell growth mediated by adipose factors. Serum concentrations of resistin have been reported to be markedly elevated in obese mice and can be decreased by treatment with thiazolidines. Importantly, the intensity of resistin expression is significantly increased in prostate cancer compared with BPH tissue which enables it a novel cancer marker and interesting therapeutic target of bladder cancer. Furthermore, the increased level of blood resistin is constantly associated with poor outcomes.
Resistin for Sepsis Diagnosis
Different studies have reported the role of resistin as a potential diagnostic marker of sepsis. Sundéncullberg et al. (2007) assessed systemic levels of resistin in patients with septic shock/severe sepsis and found that resistin may be a marker of severity of disease and possibly a mediator of the prolonged inflammatory state seen in infected critically ill patients. Aliefendioglu et al. (2014) assessed resistin levels in premature newborns that are considered to have sepsis. The results showed that resistin levels were higher in premature newborns with sepsis and correlated with IL-6 levels, which is an indicator of neonatal sepsis. The findings suggest that resistin may also be used in the diagnosis of neonatal sepsis, although it may have limited value when compared with other inflammatory markers such as IL-6 and procalcitonin.
Features of IVD Antibody Development Services
IVD Antibody Development Services Targeting Resistin Marker
Biomarkers are potentially useful along the whole spectrum of the disease process. Before diagnosis, markers could be used for screening and risk assessment. During diagnosis, markers can determine staging, grading, and selection of initial therapy. Later, they can be used to monitor therapy, select an additional therapy, or monitor recurrent diseases. As a leading company in the field of IVD development, Creative Biolabs provides a full range of high-quality IVD antibody development services of resistin marker for the diagnosis of bladder cancer and sepsis. Our professional and experienced scientists will work closely with you to promote your programs a success.
Constantly looking for new technologies and applications, Creative Biolabs puts our expertise in the development of new antibodies and assays to measure relevant biomarkers of different diseases and infections. Besides resistin, we can customize antibodies against other clinically relevant biomarkers. If you are interested in our services, contact us and we would be happy to help.
References
For Research Use Only.
